Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 7/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 1/20 | 1.00 |
| ▸ | PTGFR | P43088 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517904 | 1.00 | PTGER4 (1.00) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| Diethylamine SCHEMBL2110430 | 0.95 | PTGER4 (0.90) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL2110525 | 0.91 | PTGER4 (0.82) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL10019019 | 0.90 | PTGER4 (0.81) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL10019023 | 0.89 | PTGER4 (0.85) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL10019020 | 0.88 | PTGER4 (1.00) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL2109496 | 0.88 | PTGER4 (0.84) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL31366898 | 0.87 | PTGER4 (0.80) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL2111190 | 0.87 | PTGER4 (0.98) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL25373714 | 0.87 | PTGER4 (0.77) | PTGER4PTGDRPTGER2TBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342196-A1 | TARGETING SELECT LIPID SIGNALING TO COUNTER TYPE 1 DIABETES (T1D) | UAB RES FOUND (US) | 2024-10-17 | — | — | US | claimed |
| WO-2025229177-A1 | CRYSTALLINE FORMS OF AN N-SUBSTITUTED INDOLE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-06 | — | — | WO | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2025-03-04 | — | — | US | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240342196-A1 | TARGETING SELECT LIPID SIGNALING TO COUNTER TYPE 1 DIABETES (T1D) | UAB RES FOUND (US) | 2024-10-17 | — | — | US | disclosed |
| EP-3889134-B1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | KEYTHERA SUZHOU PHARMACEUTICALS CO LTD (CN) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | disclosed |
| CN-113896673-B | Amide derivatives as prostaglandin EP4 receptor antagonists and uses thereof | 安润医药科技（苏州）有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-8158671-B2 | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK CANADA INC. (CA) | 2012-04-17 | — | — | US | disclosed |
| WO-2010121382-A1 | PROCESS FOR MAKING INDOLE CYCLOPROPYL AMIDE DERIVATIVES | MERCK FROSST CANADA LTD. (CA) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121382-A1 | PROCESS FOR MAKING INDOLE CYCLOPROPYL AMIDE DERIVATIVES | MERCK FROSST CANADA LTD. (CA) | 2010-10-28 | — | — | WO | disclosed |
| CN-101622230-A | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD | 2010-01-06 | — | — | CN | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| EP-2114877-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | PTGER4 190/4885PTGDR 163/4885PTGER2 17/4885 |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGDR 10/4885PTGER2 4/4885 |
| US-20240342196-A1 | TARGETING SELECT LIPID SIGNALING TO COUNTER TYPE 1 DIABETES (T1D) | DGKB, PLIN1, SPTLC1 | PTGER4 3285/4885PTGDR 2279/4885PTGER2 3985/4885 |
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | PTGER4, PTGER1, PTGES | PTGER4 1/4885PTGDR 15/4885PTGER2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.